OncoVerity
Aurora
About OncoVerity
OncoVerity focuses on optimizing and advancing the development of cusatuzumab, a novel anti-CD70 antibody.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $44.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2024)
- Website: oncoverity.com
- Phone: 720-859-4105
Industries & Categories
Health Care, Medical, Therapeutics
Canonical: https://fsome.com/organization/oncoverity-65795 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.